Bill
HR 2821
The FDA Modernization Act 3.0 streamlines drug and device approvals, enhancing patient access to innovative treatments and improving FDA efficiency and transparency.
Bill Number: HR 2821
Introduced On: April 10, 2025
Current Status: Introduced in House
Referred To: House Committee on Energy and Commerce
The FDA Modernization Act 3.0 aims to enhance the efficiency and effectiveness of the U.S. Food and Drug Administration (FDA) in regulating drugs and medical devices. The bill seeks to modernize the FDA's processes to better respond to advancements in science and technology, ensuring that patients have timely access to safe and effective treatments.
While the full text of the bill is not provided, the following key provisions are typically included in modernization efforts:
Streamlined Approval Processes: The bill may propose changes to expedite the review and approval of new drugs and medical devices, potentially reducing the time it takes for innovations to reach the market.
Enhanced Regulatory Flexibility: It could introduce more flexible regulatory pathways for breakthrough therapies and devices, allowing for adaptive trial designs and real-world evidence to support approvals.
Increased Transparency: The legislation may call for improved transparency in the FDA's decision-making processes, including clearer communication with stakeholders about regulatory requirements and timelines.
Focus on Patient-Centric Approaches: The bill may emphasize the importance of patient input in the drug development process, ensuring that treatments align with patient needs and preferences.
Pharmaceutical and Biotech Companies: The bill is likely to impact companies involved in drug and medical device development by altering regulatory requirements and approval timelines.
Healthcare Providers: Physicians and healthcare professionals may benefit from quicker access to new therapies, enhancing treatment options for patients.
Patients: Ultimately, patients could experience improved access to innovative treatments and therapies, potentially leading to better health outcomes.
Committee Review: Following its introduction, HR 2821 has been referred to the House Committee on Energy and Commerce for further consideration. This committee will review the bill, hold hearings, and may propose amendments before it is brought to the House floor for a vote.
Timeline: As of now, there is no specified timeline for when the committee will act on the bill or when it may be scheduled for a vote in the House.
The bill is sponsored by Earl L. "Buddy" Carter and has multiple cosponsors, including notable members such as:
The FDA Modernization Act 3.0 represents a significant effort to update and improve the regulatory framework governing the approval of drugs and medical devices in the United States. By streamlining processes and enhancing patient access to innovative therapies, the bill aims to foster a more responsive and efficient FDA. Further developments will depend on the committee's review and subsequent legislative actions.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
